Jul 18,2018

VA and IBM Watson Health Extend Partnership to Support Veterans With Cancer

Today the U.S. Department of Veterans Affairs and IBM Watson Health announced the extension of a public-private partnership to apply artificial intelligence (AI) to help interpret cancer data in the treatment of Veteran patients. VA's precision oncology program primarily supports stage 4 cancer patients who have exhausted other treatment options. The partnership extension with IBM will enable VA oncologists to continue using Watson for Genomics through at least June 2019.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 25,2023

AI-powered pop up clinic launched to detect skin cancer in South Australia

Health charity Skin Check Champions, the University of South Australia, and The Hospital Research Foundation have teamed up to launch a pop-up clinic that uses AI to diagnose skin cancer. Their pop-up clinic is led by nurses who take high-quality lesion images from patients, which are then triaged and conditionally diagnosed by AI algorithms to check if they are cancerous. The results are also verified by local GPs. "Our goal is to halve the number of Aussies who die from melanoma and increase the number of skin checks in Australia by 25% by running a targeted AI-supported national skin check programme," said Skin Check Champions CEO Scott Maggs.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 06,2023

Intrasense : and the ICM sign a partnership to optimize a new solution dedicated to oncology

Intrasense, a specialist in medical imaging software solutions, has joined forces with the Montpellier Cancer Institute (ICM) through a partnership aimed at validating and then deploying its new platform dedicated to oncology in real-life situations, with the objective of using it in clinical routine. The new platform is designed to streamline and simplify the care process related to medical imaging in oncology. It will provide oncology professionals with a full range of clinical, collaborative and research tools, perfectly addressing all aspects of patient management. The medical teams of the ICM were asked to evaluate the prototype and the first versions of the solution with the ambition to use it in their daily practice. Initial evaluations of the prototype by the ICM teams have highlighted the need for an intelligent user interface and tools that are perfectly adapted to the expectations of radiologists in oncology practice. Further tests will be carried out throughout the year with a view to marketing a software platform enhanced with innovative functionalities in early 2024.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Jan 31,2023

Guardant Health to integrate Lunit's AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection

Lunit, in partnership with leading precision oncology company Guardant Health, today announced the integration of its AI-based PD-L1 scoring algorithm into Guardant's testing workflow to enhance biomarker detection in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer. The newly integrated algorithm will enable Guardant to offer augmented biomarker assessment for NSCLC patients through AI-based quantification of tissue samples using a scoring system generated by Lunit SCOPE PD-L1. The enhanced Guardant test is designed to support pathologists in diagnosing PD-L1 status with higher accuracy and efficiency. Through the AI software, the test showed improved detection of PD-L1 by more than 20 percent compared to manual pathologist interpretation in the most challenging cases in NSCLC.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Feb 09,2023

Ibex's Galen™ Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR

Ibex Medical Analytics today announced that Galen™ Prostate is now CE marked under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for supporting pathologists in primary diagnosis of prostate biopsies. Galen Prostate is the first standalone AI-based cancer diagnostics product of its kind certified under the IVDR. IVDR is the new regulatory standard set by the European Union, replacing the previous In Vitro Diagnostic Medical Device Directive (IVDD). During 2023, Ibex plans to migrate additional products, including its Galen Breast and Galen Gastric solutions, under the IVDR certificate. Galen Prostate uses AI to analyze biopsies ahead of pathologists' review, providing them with diagnostic insights to guide their diagnosis.

REGULATORY CE MARK

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 15,2023

Macmillan invests in Neutrocheck device for home-testing neutropenic sepsis

Macmillan Cancer Support, the cancer charity, has invested in Neutrocheck – a portable device and accompanying app in development from 52 North Health – with the aim to help people with cancer test their risk of life-threatening neutropenic sepsis at home rather than at hospital. Macmillan’s £100,000 investment in Neutrocheck is the first for the charity’s new Innovation Impact Investment Portfolio. By investing in this way, Macmillan hopes to play a critical role in developing new ways to transform the lives of people with cancer, and inspire other organisations and investors to support innovation in cancer care. 

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Verana Health Announces Release of Qdata Module for Non-Muscle Invasive Bladder Cancer RWE Analysis

Verana Health—a digital health company elevating quality in real-world data (RWD)—today announced that a Urology Qdata module is available to help support clinical research surrounding non-muscle invasive bladder cancer (NMIBC). Exclusive insights into more than 50,000 de-identified patients with NMIBC are derived from key variables extracted from unstructured clinician notes including diagnosis date, treatments, recurrences, documented T stage, and tumor grade for risk determination. Qdata NMIBC is powered by the American Urological Association's (AUA) Quality Registry (AQUA), the world's largest real-world clinical data registry for urology.

PRODUCT

#rwd

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Feb 16,2023

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

 Oatmeal Health’s Co-Founder and CEO Dr. Ty Vachon speaks about the company’s mission and how its AI-powered solution is working with FQHCs, health plans, and employers to help underserved patients get screened for chronic disease and cancer. 

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 02,2023

C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan

C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research. Under this agreement, RG will work with C2i Genomics to commercialize its C2intelligence cloud-based platform and the C2inform MRD test for pharmaceutical and clinical research and eventually for commercial clinical testing in Japan. C2i’s technology allows cancer tumor burden monitoring using ultra-sensitive whole genome sequencing for personalized medicine and accelerated drug development.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

AI Predicts Cancer Patient Survival by Reading Doctor's Note

A team of researchers from the University of British Columbia and BC Cancer have developed an artificial intelligence (AI) model that predicts cancer patient survival more accurately and with more readily available data than previous tools. The model uses natural language processing (NLP) - a branch of AI that understands complex human language - to analyze oncologist notes following a patient’s initial consultation visit - the first step in the cancer journey after diagnosis. The model uses natural language processing (NLP) - a branch of AI that understands complex human language - to analyze oncologist notes following a patient’s initial consultation visit - the first step in the cancer journey after diagnosis.

CLINICAL STUDY

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY